Revelation Biosciences Inc. announced positive results for REVTx-300 in a preclinical model of acute kidney injury (AKI), a type of chronic kidney disease (CKD).
Transcenta Holding Ltd. has received IND clearance from the FDA for TST-004, its best-in-class, humanized monoclonal antibody targeting mannose-binding protein-associated serine protease 2 (MASP2), for IgA nephropathy (IgAN).
Understanding how alternative splicing is regulated and how it contributes to disease pathogenesis might open new therapeutic options for the treatment of diabetic nephropathy (DN). Bcl-2-like protein 1 (BCL2L1), also known as BCLX, for which two alternative splicing forms (Bcl-xL and Bcl-xS) have been seen to have antagonistic effects.
Klotho Therapeutics Inc. has synthesized new histone deacetylase 8 (HDAC8) inhibitors reported to be useful for the treatment of acute kidney injury and chronic kidney disease.
Maze Therapeutics has patented apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, HIV-associated nephropathy, lupus nephritis and sepsis.
Sphingosine 1-phosphate (S1P) is a pleiotropic mediator involved in a variety of cellular functions. It is a product of cell membrane sphingolipid catabolism as it is generated from sphingosine intracellularly by sphingosine kinases 1 and 2 (SphK1 and SphK2), and it is exported from cells by spinster homolog 2 (Spns2) or major facilitator superfamily 2b (Mfsd2b).
C3 glomerulopathy (C3G) is a group of rare kidney diseases characterized by complement dysregulation and predominant C3 deposition in the kidney tissue.
Researchers from Kira Pharmaceuticals LLC and University of Pennsylvania have developed a novel mouse model of rapidly progressing lethal C3 glomerulopathy (C3G), with the aim of assessing whether inhibition of proximal alternative pathway (AP) complement components such as factor D (FD) may be more efficacious than C5 inhibition for the treatment of C3G.
Terumo Blood and Cell Technologies (Terumo BCT) is teaming up with Eliaz Therapeutics Inc. to develop and commercialize a new type of apheresis treatment for acute kidney injury (AKI) and sepsis-induced acute kidney injury (S-AKI). The exclusive collaboration aims to reduce long-term morbidity and death in patients with AKIs by removing an upstream inflammatory protein called Galectin-3 (Gal-3) from blood plasma.